KM 023 - Kamari Pharma
Alternative Names: KM-023 - Kamari PharmaLatest Information Update: 24 May 2024
At a glance
- Originator Kamari Pharma
- Class Skin disorder therapies; Small molecules
- Mechanism of Action TRPV3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ichthyosis; Palmoplantar keratoderma
Most Recent Events
- 17 May 2024 Pharmacodynamics and adverse events data from preclinical trial in Palmoplantar keratoderma released by Kamari Pharma
- 01 May 2024 Kamari Pharma plans phase I trials for Olmstead syndrome, Palmoplantar keratodermas and Ichthyosis
- 22 Apr 2024 KM 023 - Kamari Pharma is available for licensing as of 22 Apr 2024. https://kamaripharma.com/partnership/ (Kamari Pharma pipeline, April 2024)